Docket Number: 037003-0308678

PATENT APPLICATION

Client Reference: 2002-30-0048A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of BRASLAWSKY et al.

Group Art Unit: Unassigned

Application No.: 10/796,158

Examiner: Unassigned

Filed: March 10, 2004

Confirmation No.:

For: THIOL-MEDIATED DRUG ATTACHMENT TO TARGETING PEPTIDES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the filing date of the application and before the mailing date of the first official action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: April 5, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	0308678	2002-30-0048A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: BRASLAWSKY et al.

Appln. No.: 10/796,158

Filing Date: March 10, 2004

Date: April 5, 2004 Page 1 of 2

Examiner: Unassigned | Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	4,485,101	11/1984	Coy			
	BR	4,853,371	08/1989	Coy			
	CR	4,871,717	10/1989	Coy			
	DR	4,904,642	02/1990	Coy			
	ER	5,073,541	12/1991	Taylor			
	FR	5,411,943	05/1995	Bogden			
	GR	5,428,019	06/1995	Edwards			
	HR	5,597,894	01/1997	Coy			
	IR	5,620,675	04/1997	McBride			
	JR	5,633,263	05/1997	Coy			
	KR	5,708,135	01/1998	Coy			
	LR	5,716,596	02/1998	Dean			
	MR	5,723,578	03/1998	Coy			
	NR	5,750,499	05/1998	Hoeger			
	OR	5,770,687	06/1998	Hornik			
	PR	5,820,845	10/1998	Dean			
	QR	5,830,431	11/1998	Srinivasan			
	RR	6,001,801	12/1999	Coy			
	SR	6,024,938	02/2000	Corbo			
	TR	6,277,356	08/2001	Albert			
	UR	6,307,017	10/2001	Coy			
	VR	6,309,633	10/2001	Ekwuribe			
	WR	6,465,613	10/2002	Coy			

FOREIGN PATENT DOUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	No
	XR									
	YR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	ZR	Bakker WH, et al., "Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals," *J Nucl Med*, 1990, 31: 1501-9.
	AAR	Behr, TM, et al., "Imaging tumors with peptide-based radioligands," *Q J Nucl Med.*, 2001, 45:189-200.
	BBR	Breeman, WAP, et al.,."Studies on radiolabeled somatostatin analogues in rats and in patients," *Q J Nucl Med.*, 1996, 40:209-20.
	CCR	Bruns C, et al., "Molecular pharmacology of somatostatin-receptor subtypes," *Ann N Y Acad Sci*, 1994, 733: 138-46.
	DDR	Buscail L, et al., "Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2," *Proc Natl Acad Sci U S A*, 1994, 91: 2315.

	EER	...cail L, et al., "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms," *Proc Natl Acad Sci U S A*, 1995, 92: 1580-4.
	FF	Chattopadhyay S, et al., "Purification and stabilization of 99mTc-d,1-HMPAO: role of organic extractants," *Nucl Med Biol*, 28:741-744.
	GGR	Davies N, et al., "Therapeutic potential of octreotide in the treatment of liver metastases," *Anticancer Drugs*, 1996, 7 Suppl 1: 23-31.
	HHR	Decristoforo C, et al., "99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution," *Nucl Med Biol*, 1999, 26: 389-96.
	IIR	Dewanjee MK, et al., "Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model," *J Nucl Med*, 1994, 35: 1054-63.
	JR	Hammond PJ, et al., "Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue," *Br J Cancer*, 1993, 67: 1437-9.
	KKR	Jenkins SA, et al., "Somatostatin analogs in oncology: A look to the future," *Chemotherapy*, 2001, 47 Suppl 2: 162-96.
	LLR	Kahan Z, et al., "Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238," *Int J Cancer*, 1999, 82: 592-8.
	MMR	Kiaris H, et al., "A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice," *Eur J Cancer*, 2001, 37: 620-8.
	NNR	Krenning EP, et al., "Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin," *Lancet*, 1989, 1: 242-4.
	OOR	Krenning EP, et al., "Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients," *Eur J Nucl Med*, 1993, 20: 716-31.
	PPR	Kwekkeboom D, et al., "Peptide receptor imaging and therapy," *J Nuclear Med*, 2000, 41:1704-13.
	QQR	Lee JM, et al., "A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice," *Anticancer Res*, 1993, 13: 1453-6.
	RRR	Nagy A, et al., "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubiciin," *Proc Natl Acad Sci U S A*, 1998, 95:1794-99.
	SSR	Otte A, et al., "DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy," *European J Nucl Med*, 1997, 24:792-5.
	TTR	Patel YC, et al., "The somatostatin receptor family," *Life Sci*, 1995, 57: 1249-65.
	UUR	Patel YC, "Molecular pharmacology of somatostatin receptor subtypes," *J Endocrinol Invest*, 1997, 20: 348-67.
	VVR	Plonowski A, et al., "Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238," *Cancer Res*, 1999, 59: 1947-53.
	WWR	Plonowski A, et al., "Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238," *Cancer Res*, 2000, 60: 2996-3001.
	XXR	Plonowski A, et al., "Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238," *Int J Oncol*, 2002, 20: 397-402.
	YYR	Reisine T, et al., "Molecular biology of somatostatin receptors," *Endocr Rev*, 1995, 16: 427-42.
	ZZR	Reubi JC, et al., "Somatostatin receptors in human prostate and prostate cancer," *J Clin Endocrinol Metab*, 1995, 80: 2806-14.
	AAAR	Reubi JC, et al., "Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels," *Metabolism*, 1996, 45: 39-41.
	BBBR	Sagiuchi T, et al., "Transient seizure activity demonstrated by Tc-99m HMPAO SPECT and diffusion-weighted MR imaging," *Ann Nucl Med*, 2001, 15: 267-70.
	CCCR	Smith-Jones PM, et al., "Synthesis, biodistribution and renal handling of various chelate-somatostatin conjugates with metablolizable linking groups," *Nuc Med Biol*, 1997, 24:761-69.
	DDDR	Smith-Jones PM, et al., "Synthesis and characterisation of [90Y]-Bz-DTPA-oct: A Yttrium-90-Labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours," *Nuc Med Biol*, 1998, 25:181-8.
	EEER	Srkalovic G, et al., "Evaluation of receptors for somatostatin in various tumors using different analogs," *J Clin Endocrinol Metab*, 1990, 70: 661-9.
	FFFR	Stewart GJ, et al., "Octreotide inhibits development of hepatic metastases from a human colonic cancer cell line," *Br J Surg*, 1994, 81: 1332.
	GGGR	Szepeshazi K, et al., "Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers," *Clin Cancer Res*, 2001, 7: 2854-61.
	HHHR	Virgolini I, et al., "New trends in peptide receptor radioligands," *Q J Nucl Med*, 2001, 45:153-9.
	IIIR	Weckbecker G, et al., "Somatostatin analogs for diagnosis and treatment of cancer," *Pharmacol Ther*, 1993, 60: 245-64.
	JJJR	Yoo TM, et al., "Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment," *J Nucl Med*, 1997, 38: 294-300.

Examiner	Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.